NCT03148860View on ClinicalTrials.gov

Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA

PHASE3CompletedINTERVENTIONAL

Enrollment

186

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

April 12, 2021

Study Completion Date

October 21, 2021

Conditions

Psoriatic Arthritis

Interventions

DRUG

Methotrexate

subjects will receive once weekly 15 mg (3 capsules) MTX

DRUG

Ustekinumab

subject will receive Ustekinumab open-label over a treatment period of 52 weeks

OTHER

Placebo

subjects will receive once weekly 3 capsules PLC to MTX

Trial Locations (1)

60526

CIRI, Frankfurt am Main

All Listed Sponsors

collaborator

Janssen-Cilag Ltd.

INDUSTRY

lead

Dr. Frank Behrens

OTHER

NCT03148860 - Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA | Biotech Hunter | Biotech Hunter